Bio-Techne (TECH)

Decent, safe work
C (53)
Screens
Advertising
Alcohol
Animal treatment
Anti-abortion support
Anti-personnel mines
Antisemitism
Arctic drilling
Biological and chemical weapons
Cannabis
Carbon emissions intensity
Cluster munitions
Coal
Contraceptives
Controversial weapons
Deforestation - financing
Depleted uranium
Discrimination controversies
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Military contracting
Misleading communication
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
UK sanctions list
Undermining US elections
US OFAC sanctions list
Weapons
Impact

Cause TECH
Peer rank
Decent, safe work

Name Rating
Loading...
Screens
Advertising
Alcohol
Animal treatment
Anti-abortion support
Anti-personnel mines
Antisemitism
Arctic drilling
Biological and chemical weapons
Cannabis
Carbon emissions intensity
Cluster munitions
Coal
Contraceptives
Controversial weapons
Deforestation - financing
Depleted uranium
Discrimination controversies
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Military contracting
Misleading communication
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
UK sanctions list
Undermining US elections
US OFAC sanctions list
Weapons
TECH Price
$63.52
Last available end-of-day price. Full disclosure
Revenue
$1.14 billion
Market cap
$11.69 billion
Public/private
Public
Hypothetical historical growth of $10,000
Historical performance
Company
Founded
1976
Employees
3,200
Sector
Healthcare
Industry
Pharmaceuticals & Biotech
Peer group
Biotechnology
SASB industry
Medical Equipment & Supplies
Headquarters
Minnesota, United States
Share classes
TECH
Mission
Providing innovative scientific solutions to better understand biological processes and enable discovery
Description
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Material causes
Ethos considers the following causes material for Bio-Techne, based on its industry peer group Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.